Cyramza (ramucirumab) [product information]. EMA.

Regulatory approval published by the European Medicines Agency.

Citation

Eli Lilly Nederland B.V. Cyramza (ramucirumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf. Revised December 2022. Accessed March 7, 2024.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab